The volatility surrounding Spanish pharmaceutical firm Grifols continues as the company’s shares fell 13% following the collapse of takeover talks with private equity firm Brookfield. This decline underscores the lingering impact of a high-profile short report published by Gotham City Research earlier this year. The report alleged that Grifols had manipulated its debt and earnings reporting by consolidating profits from businesses sold to a vehicle owned by the founding family. These allegations, which Grifols has consistently denied, claimed the company’s debt-to-earnings ratio was significantly higher than reported—potentially exceeding a multiple of 10 rather than the stated six. Since the report's release in January, Grifols has seen its market valuation plummet, losing over €3 billion in value. The situation has drawn the attention of Spanish regulators, who have launched an investigation into the company's financial disclosures. The failure of the Brookfield deal suggests that the "short-seller discount" remains a significant hurdle for companies facing credible forensic scrutiny. For investors, the Grifols saga serves as a case study in how activist research can trigger a long-term "de-rating" of a stock, even when the company maintains its innocence. The Forensic Ledger observes that the market's reaction to the failed takeover reflects a lack of confidence in the company's balance sheet transparency, a direct consequence of the initial forensic allegations that have yet to be fully resolved by regulatory authorities.
Original reporting by pharmaphorum. This article is desk analysis prepared by The Forensic Ledger from publicly available sources, summarized with citation to the original.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.
